Prospective Observational Study To Explore The Effectiveness Of Eribulin As First- Or Second- Line Chemotherapy In Patients With Her2-Negative Hormone-Resistant Advanced Or Metastatic Breast Cancer (Kbcrn A001: E-Spec Study)